These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36779500)

  • 21. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
    Sterling TR; Moro RN; Borisov AS; Phillips E; Shepherd G; Adkinson NF; Weis S; Ho C; Villarino ME;
    Clin Infect Dis; 2015 Aug; 61(4):527-35. PubMed ID: 25904367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isoniazid and Rifapentine Treatment Eradicates Persistent
    Foreman TW; Bucşan AN; Mehra S; Peloquin C; Doyle LA; Russell-Lodrigue K; Gandhi NR; Altman J; Day CL; Ernst JD; Blumberg HM; Rengarajan J; Kaushal D
    Am J Respir Crit Care Med; 2020 Feb; 201(4):469-477. PubMed ID: 31647877
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment for Tuberculosis Infection With 3 Months of Isoniazid and Rifapentine in New York City Health Department Clinics.
    Stennis NL; Burzynski JN; Herbert C; Nilsen D; Macaraig M
    Clin Infect Dis; 2016 Jan; 62(1):53-59. PubMed ID: 26338781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implementing 3HP vs. IPT as TB preventive treatment in Pakistan.
    Jaswal M; Farooq S; Madhani F; Noorani S; Salahuddin N; Amanullah F; Khowaja S; Safdar N; Khan A; Yuen C; Keshavjee S; Becerra M; Hussain H; Malik AA
    Int J Tuberc Lung Dis; 2022 Aug; 26(8):741-746. PubMed ID: 35898140
    [No Abstract]   [Full Text] [Related]  

  • 25. Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review.
    Hamada Y; Ford N; Schenkel K; Getahun H
    Int J Tuberc Lung Dis; 2018 Dec; 22(12):1422-1428. PubMed ID: 30606313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrating 3HP-based tuberculosis preventive treatment into Zimbabwe's Fast Track HIV treatment model: experiences from a pilot study.
    Mapingure MP; Zech JM; Hirsch-Moverman Y; Msukwa M; Howard AA; Makoni T; Gwanzura C; Apollo T; Sandy C; Musuka GN; Rabkin M
    J Int AIDS Soc; 2023 Jun; 26(6):e26105. PubMed ID: 37339341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa.
    Asare K; Lewis L; van der Molen J; Sookrajh Y; Khubone T; Moodley P; Lessells RJ; Naidoo K; Sosibo P; Garrett N; Dorward J
    Open Forum Infect Dis; 2023 Dec; 10(12):ofad583. PubMed ID: 38045558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection.
    Borisov AS; Bamrah Morris S; Njie GJ; Winston CA; Burton D; Goldberg S; Yelk Woodruff R; Allen L; LoBue P; Vernon A
    MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(25):723-726. PubMed ID: 29953429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of double-dose dolutegravir in people receiving rifampin-based tuberculosis treatment: an observational, cohort study of people with HIV from six countries.
    Shah NS; Kityo C; Hughes MD; McCarthy C; Wallis C; Hosseinipour M; Langat D; Nyirenda M; Rassool M; Dawson R; Joseph Y; Some F; Mngqbisa R; Mukwekwerere PG; Woolley E; Godfrey C; Manabe YC; Mellors JW; Flexner C; Maartens G;
    Clin Infect Dis; 2024 May; ():. PubMed ID: 38739755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study.
    Lam CK; McGinnis Pilote K; Haque A; Burzynski J; Chuck C; Macaraig M
    J Med Internet Res; 2018 Nov; 20(11):e287. PubMed ID: 30459146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting.
    Pease C; Alvarez G; Mallick R; Patterson M; Finn S; Habis Y; Schwartzman K; Kilabuk E; Mulpuru S; Zwerling A
    BMJ Open; 2021 May; 11(5):e047514. PubMed ID: 33986067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.
    Scriba TJ; Fiore-Gartland A; Penn-Nicholson A; Mulenga H; Kimbung Mbandi S; Borate B; Mendelsohn SC; Hadley K; Hikuam C; Kaskar M; Musvosvi M; Bilek N; Self S; Sumner T; White RG; Erasmus M; Jaxa L; Raphela R; Innes C; Brumskine W; Hiemstra A; Malherbe ST; Hassan-Moosa R; Tameris M; Walzl G; Naidoo K; Churchyard G; Hatherill M;
    Lancet Infect Dis; 2021 Mar; 21(3):354-365. PubMed ID: 33508224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials.
    Moro RN; Scott NA; Vernon A; Tepper NK; Goldberg SV; Schwartzman K; Leung CC; Schluger NW; Belknap RW; Chaisson RE; Narita M; Machado ES; Lopez M; Sanchez J; Villarino ME; Sterling TR
    Ann Am Thorac Soc; 2018 May; 15(5):570-580. PubMed ID: 29393655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection.
    Sadowski C; Belknap R; Holland DP; Moro RN; Chen MP; Wright A; Millet JP; Caylà JA; Scott NA; Borisov A; Gandhi NR
    Clin Infect Dis; 2023 Jun; 76(12):2090-2097. PubMed ID: 36815322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in Uganda.
    Musinguzi A; Aschmann HE; Kadota JL; Nakimuli J; Welishe F; Kakeeto J; Namale C; Akello L; Nakitende A; Berger C; Katamba A; Tumuhamye J; Kiwanuka N; Dowdy DW; Cattamanchi A; Semitala FC
    IJTLD Open; 2024 Feb; 1(2):83-89. PubMed ID: 38966690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Annual Tuberculosis Preventive Therapy for Persons With HIV Infection : A Randomized Trial.
    Churchyard G; Cárdenas V; Chihota V; Mngadi K; Sebe M; Brumskine W; Martinson N; Yimer G; Wang SH; Garcia-Basteiro AL; Nguenha D; Masilela L; Waggie Z; van den Hof S; Charalambous S; Cobelens F; Chaisson RE; Grant AD; Fielding KL;
    Ann Intern Med; 2021 Oct; 174(10):1367-1376. PubMed ID: 34424730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
    Tseng SY; Huang YS; Chang TE; Perng CL; Huang YH
    J Chin Med Assoc; 2021 Nov; 84(11):993-1000. PubMed ID: 34747900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial.
    Hosseinipour MC; Bisson GP; Miyahara S; Sun X; Moses A; Riviere C; Kirui FK; Badal-Faesen S; Lagat D; Nyirenda M; Naidoo K; Hakim J; Mugyenyi P; Henostroza G; Leger PD; Lama JR; Mohapi L; Alave J; Mave V; Veloso VG; Pillay S; Kumarasamy N; Bao J; Hogg E; Jones L; Zolopa A; Kumwenda J; Gupta A;
    Lancet; 2016 Mar; 387(10024):1198-209. PubMed ID: 27025337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the effect of short-course rifapentine-based regimens with or without enhanced behaviour-targeted treatment support on adherence and completion of treatment for latent tuberculosis infection among adults in the UK (RID-TB: Treat): protocol for an open-label, multicentre, randomised controlled trial.
    Rangaka MX; Hamada Y; Duong T; Bern H; Calvert J; Francis M; Clarke AL; Ghanouni A; Layton C; Hack V; Owen-Powell E; Surey J; Sanders K; Booth HL; Crook A; Griffiths C; Horne R; Kunst H; Lipman M; Mandelbaum M; White PJ; Zenner D; Abubakar I
    BMJ Open; 2022 Sep; 12(9):e057717. PubMed ID: 36691120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of implementation of a 12-dose once-weekly treatment (3HP) in addition to standard regimens to prevent TB on completion rates: Interrupted time series design.
    Alvarez GG; Sullivan K; Pease C; Van Dyk D; Mallick R; Taljaard M; Grimshaw JM; Amaratunga K; Allen C; Brethour K; Mulpuru S; Pakhale S; Aaron SD; Cameron DW; Alsdurf H; Hui C; Zwerling AA
    Int J Infect Dis; 2022 Apr; 117():222-229. PubMed ID: 35121126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.